Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 17, 2025

Intermediate-High-Dose Cyclophosphamide for Stem Cell Mobilization in Lymphoma: A Single-Center Retrospective Study

View Full Paper
Ask AI
Bookmark
Share

Authors

YPYuyang PangShanghai Jiao Tong UniversityHZHui ZhouShanghai Jiao Tong UniversityLMLiyuan MaNorth University of China

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows comparable mobilization success in lymphoma patients, suggesting 3 g/m² cyclophosphamide is safer than 4 g/m².

Key Points

  • Cyclophosphamide at 3 g/m² demonstrated a comparable success rate of stem cell mobilization in lymphoma patients.
  • The mobilization success rates were similar at 83.6% for 3 g/m² and 88.4% for 4 g/m², indicating effective strategies.
  • Patients with 4 g/m² cyclophosphamide experienced significantly lower blood cell counts during the procedure, highlighting safety concerns.
  • The results support the utilization of cyclophosphamide at lower doses for safer mobilization without compromising efficacy.

Cite This Study

Pang et al. (2025) studied this question.

synapsesocial.com/papers/68a36c360a429f797333084fhttps://doi.org/10.21203/rs.3.rs-7227721/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma2015 · 352 citations
  2. 2Twenty-five years of peripheral blood stem cell transplantation2011 · 168 citations
  3. 3Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update2021 · 36 citations
  4. 4Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure2016 · 37 citations
  5. 5Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study2021 · 36 citations